Abstract
As of October 2020, coronavirus disease 2019 (COVID-19) has caused over 43 million infections and over 1.1 million deaths worldwide. Remdesivir (GS-5734), a nucleotide prodrug that inhibits RNA-dependent RNA polymerase, accelerates recovery in patients with moderate to severe COVID-19 and was approved by emergency use authorization in May 2020.1,2 However, all studies of remdesivir have excluded patients with kidney impairment using estimated glomerular filtration rate (eGFR) cutoffs of 30 or 50 mL/min per 1.73 m2 because of theoretical concerns about the accumulation of remdesivir’s active metabolite or its sulfobutylether-beta-cyclodextrin carrier.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
